Navata
← All Library

Validation & Evidence

How Should Test Data Be Controlled in GxP System Validation?

AI-assisted research and drafting · Practitioner reviewed by Rohith Karanam Sreedhar · 16 September 2026

ⓘ Library content is researched and drafted with AI assistance and reviewed by a Navata practitioner before publication. For original analysis and long-form practitioner perspectives, visit Navata Insights →

A well-written test can still produce weak assurance if its data never challenges the conditions that matter. Test data is not neutral input. It determines which parts of the behaviour are actually exercised.

Design data from the assurance claim

Start with the requirement, risk or failure condition. Identify the data characteristics that can change the outcome: value range, status, record type, role ownership, date, combination of fields, missing values, duplicate identifiers, volume or relationship to other records.

A representative set does not mean a random sample of realistic-looking records. It means a population deliberately selected to expose the behaviour relevant to the claim.

Include boundary and failure-provoking data

Normal examples prove only normal behaviour. Where risk depends on limits or exceptions, include values at and around boundaries, invalid inputs, missing dependencies, duplicates, unexpected sequences and combinations known to stress the rule.

EMA's clinical-trial computerised-systems guideline gives a concrete example for dosage assignment: test data should include values on the borderline between different doses where the calculation creates a safety risk. That example is domain-specific, but the underlying test-design lesson is broader: choose data that can discriminate between correct and incorrect control behaviour.

Preserve provenance and version

The retained evidence should show which test data set was used, where it came from and whether it changed between runs. If a defect is fixed and the test rerun with a different data set, the evidence should make that difference visible.

For generated or synthetic data, record the generation rule where it matters to coverage. For imported reference data, identify the source and effective version. If the test depends on a controlled vocabulary or master-data relationship, stale test data can invalidate an otherwise correct script.

Be cautious with production-derived data

Using copied production data may improve realism, but it can create privacy, confidentiality, security and data-integrity risks. Use it only when the validation need justifies the transfer and when access, masking or pseudonymisation, retention and deletion are controlled.

Do not assume masking is harmless. If the transformation changes the value distribution, relationships or boundary conditions that the test depends on, the masked set may no longer be representative.

MHRA's final GxP data-integrity guidance applies across GxP sectors and emphasises governance of data through its lifecycle. Applying those principles to copied or transformed test data means retaining context and controlling transformations that can affect meaning.

Keep test and production records distinguishable

Test records should not be capable of being mistaken for regulated production records. In non-production environments this usually follows from environment separation, but copied data, shared integrations and production verification can blur the boundary.

Where a production verification requires test records, define how they are identified, contained, excluded from regulated decisions and removed or retained under an approved rule. Never rely on an informal naming convention if downstream systems or reports can still treat the record as real.

Match data volume to the claim

A small data set may be sufficient for deterministic functional behaviour but inadequate for batch, reporting, search, performance or reconciliation claims. Conversely, millions of records add little value to a rule test if the critical condition is one boundary combination.

Use the minimum data volume that is capable of exposing the relevant failure, then add scale where scale is part of the intended assurance claim.

Important boundaries

The EMA guideline cited is specific to clinical-trial computerised systems. MHRA data-integrity guidance provides a broader GxP governance baseline, while EU GMP Annex 11 provides the GMP validation context. Local privacy and security obligations may impose additional controls on production-derived data.

Sources